Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now early-phase tilt small index

Influenza a: early-phase trial registry

1 of 11 indexed Influenza a trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #1,577 of 28,707 conditions by registered trial count.

11 US clinical trials · 1 currently recruiting · #1,577 of 28,707 conditions by registered trial count

Influenza a: 11 US clinical trials tracked, 1 recruiting.

Influenza a is the subject of 11 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most active sponsor is Evidation Health, running 2 of these trials.

Enrollment posture brief

Registry condition influenza-a

OPEN 1 | RECR 9% | LATE 1 | EARLY 4 | RANK #1577 | SPON 2

Nearest open-share peer: Advanced Cancers (9% recruiting · 11 trials)

Acute Pancreatitis81.8%Acute Stroke45.5%Acquired Brain Injury36.4%Acute Lung Injury9.1%Influenza a (this)9%
Open-enrollment share among volume-matched conditions near Influenza a

Influenza a lists 1 open slots (9% of 11 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Influenza a on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Influenza a is recruiting below its size-band peers.

    1 of 11 indexed trials (9.1%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Influenza a research.

    Evidation Health accounts for 2 of 11 trials (18.2%). 9 distinct sponsors appear on at least one study for this condition label.

  3. Typical Influenza a enrolment sits around 405 participants.

    Median target enrolment is 405 among the 11 trials that report a genuine target (sentinel values excluded). 3 of those (27.3%) plan for fewer than 100 participants.

  4. Influenza a splits between interventional and observational designs.

    7 interventional and 4 observational studies make up this index (63.6% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 13Phase 21Phase 31

Open and recent trials

11 total, page 1 of 1

RECRUITING NA 1,000 participants

A Multi-Site Clinical Evaluation of the LIAISON NES FLU A/B, RSV & COVID-19 Assay in Symptomatic Patients

DiaSorin Molecular

NCT06672692

ACTIVE NOT RECRUITING Phase 1 405 participants

A Phase I/II Study on Safety AND Immunogenicity of AZD4117 and AZD5315 Vaccines (PANDA)

AstraZeneca

NCT07128615

COMPLETED 18,157 participants

Wearable Assisted Viral Evidence (WAVE) Study A Decentralized, Prospective Study Exploring the Relationship Between Passively-collected Data From Wearable Activity Devices and Respiratory Viral Infections

Evidation Health

NCT06207929

COMPLETED 5,233 participants

Home Testing of Respiratory Illness

Evidation Health

NCT04245800

COMPLETED 1,642 participants

Detection of Influenza A, Influenza B, and RSV Using the Liat™ Assays on the Liat™ Analyzer

IQuum

NCT02067286

COMPLETED NA 447 participants

Clinical Evaluation of the Panbio™ COVID-19/Flu A&B Panel

Abbott Rapid Dx

NCT06127108

COMPLETED Phase 3 329 participants

Evaluating the Safety and Efficacy of Anti-Influenza Intravenous Hyperimmune Immunoglobulin (IVIG) in Adults Hospitalized With Influenza

National Institute of Allergy and Infectious Diseases (NIAID)

NCT02287467

COMPLETED Phase 1 206 participants

Safety and Immunogenicity of the Bris10 M2SR and Sing2016 M2SR H3N2 Monovalent Influenza Vaccines

FluGen

NCT03999554

COMPLETED Phase 2 89 participants

Study of Efficacy and Safety of IV VIS410 Plus Oseltamivir Versus Oseltamivir in Hospitalized Adults With Influenza A

Visterra

NCT03040141

COMPLETED Phase 1 25 participants

Safety and Immunogenicity of Live Influenza A Vaccine for Avian Influenza H7N7

National Institute of Allergy and Infectious Diseases (NIAID)

NCT00922259

COMPLETED 10 participants

Kinetics of the Immune Response to Inactivated Influenza Vaccine in Healthy Adults

Vanderbilt University Medical Center

NCT03743688

Phase Distribution

PhaseTrial count
Phase 1 3
Phase 2 1
Phase 3 1

Named interventions

Most-linked intervention names on Influenza a records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Placebo Other
2 trials
Panbio™ Diagnostic test
1 trials
High dose of VIS410 Drug
1 trials
Low dose of VIS410 Drug
1 trials
Influenza Vaccine Recipients Biological
1 trials
Influenza A H7N7 vaccine Biological
1 trials
Placebo for IVIG Biological
1 trials
Intravenous hyperimmune immunoglobulin (IVIG) Biological
1 trials

US sites by state

Facility locations filed on Influenza a trials. A trial with sites in several states counts in each.

California 5 trials
Virginia 4 trials
Texas 4 trials
Ohio 4 trials
Florida 4 trials
Pennsylvania 3 trials
New York 3 trials
Illinois 3 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Influenza a page

11 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Influenza a condition card totals 11 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.